BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35924867)

  • 1. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
    Grigoriadou S; Clubbe R; Garcez T; Huissoon A; Grosse-Kreul D; Jolles S; Henderson K; Edmonds J; Lowe D; Bethune C
    Clin Exp Immunol; 2022 Oct; 210(1):1-13. PubMed ID: 35924867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders.
    Bethune C; Egner W; Garcez T; Huissoon A; Jolles S; Karim Y; Jain R; Savic S; Kelley K; Grosse-Kreul D; Grigoriadou S
    Clin Exp Immunol; 2019 Jun; 196(3):328-335. PubMed ID: 30724343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.
    Edgar JDM; Richter AG; Huissoon AP; Kumararatne DS; Baxendale HE; Bethune CA; Garcez T; Misbah SA; Sorensen RU;
    J Clin Immunol; 2018 Feb; 38(2):204-213. PubMed ID: 29423883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
    Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
    Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.
    Wijetilleka S; Jayne DR; Mukhtyar C; Ala A; Bright PD; Chinoy H; Harper L; Kazmi MA; Kiani-Alikhan S; Li CK; Misbah SA; Oni L; Price-Kuehne FE; Salama AD; Workman S; Wrench D; Karim MY
    Rheumatology (Oxford); 2019 May; 58(5):889-896. PubMed ID: 30590695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
    Patel V; Cowan J
    Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
    Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
    Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.
    Wasserman RL
    Allergy Asthma Proc; 2021 Nov; 42(6):489-494. PubMed ID: 34871156
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
    Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
    J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of primary antibody deficiency by consultant immunologists in the United Kingdom: a paradigm for other rare diseases.
    Spickett GP; Askew T; Chapel HM
    Qual Health Care; 1995 Dec; 4(4):263-8. PubMed ID: 10156396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
    Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
    Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UK PID Patients: Overview of perception on IgRT and infections using short survey.
    Hodkinson JP; Griffiths PR; Narme AMI; Staiger C
    Pharmazie; 2023 Dec; 78(11):231-237. PubMed ID: 38178285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus.
    Jolles S; Michallet M; Agostini C; Albert MH; Edgar D; Ria R; Trentin L; Lévy V
    Eur J Haematol; 2021 Apr; 106(4):439-449. PubMed ID: 33453130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.
    Cinetto F; Francisco IE; Fenchel K; Scarpa R; Montefusco V; Pluta A; Wolf HM
    Expert Rev Hematol; 2023 Apr; 16(4):237-243. PubMed ID: 37009667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
    Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
    Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
    Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
    Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive activities to increase recognition of primary immunodeficiency and access to immunoglobulin replacement therapy in Poland.
    Pac M; Bernatowska E
    Eur J Pediatr; 2016 Aug; 175(8):1099-105. PubMed ID: 27357411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.